Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Myriam Labopin

Showing results (171-180 of 443) with videos related to

Pageof 45
Sort By:
Leukemia|November 16, 2019
The impact of anti-thymocyte globulin on the outcomes of Patients with AML with or without measurable residual disease at the time of allogeneic hematopoietic cell transplantationArnon Nagler, Bhagirathbhai Dholaria, Myriam Labopin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 21, 2018
Impact of Donor Type in Patients with AML Given Allogeneic Hematopoietic Cell Transplantation After Low-Dose TBI-Based RegimenFrédéric Baron, Myriam Labopin, Annalisa Ruggeri, et al.
Haematologica|September 11, 2016
Upfront autologous stem cell transplantation for newly diagnosed elderly multiple myeloma patients: a prospective multicenter studyLaurent Garderet, Eric Beohou, Denis Caillot, et al.
Vaccine|February 2, 2010
Immune response to the 23-valent polysaccharide pneumococcal vaccine after the 7-valent conjugate vaccine in allogeneic stem cell transplant recipients: results from the EBMT IDWP01 trialCatherine Cordonnier, Myriam Labopin, Virginie Chesnel, et al.
Haematologica|March 15, 2015
The impact of graft-versus-host disease prophylaxis in reduced-intensity conditioning allogeneic stem cell transplant in acute myeloid leukemia: a study from the Acute Leukemia Working Party of the European Group for Blood and Marrow TransplantationMarie Thérèse Rubio, Myriam Labopin, Didier Blaise, et al.
Bone Marrow Transplantation|June 21, 2020
The outcome of two or more HLA loci mismatched unrelated donor hematopoietic cell transplantation for acute leukemia: an ALWP of the EBMT studyArnon Nagler, Bhagirathbhai Dholaria, Myriam Labopin, et al.
Bone Marrow Transplantation|May 30, 2023
Long-term outcome of second allogeneic hematopoietic stem cell transplantation (HSCT2) for primary graft failure in patients with acute leukemia in remission: A study on behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow TransplantationArnon Nagler, Myriam Labopin, Ryszard Swoboda, et al.
Cancer|June 22, 2019
Individualized prediction of leukemia-free survival after autologous stem cell transplantation in acute myeloid leukemiaRoni Shouval, Myriam Labopin, Norbert C Gorin, et al.
Journal of Hematology & Oncology|July 6, 2019
Leukemia relapse following unmanipulated haploidentical transplantation: a risk factor analysis on behalf of the ALWP of the EBMTSimona Piemontese, Ariane Boumendil, Myriam Labopin, et al.
American Journal of Hematology|January 10, 2023
Fludarabine versus cyclophospamide in combination with myeloablative total body irradiation as conditioning for patients with acute myeloid leukemia treated with allogeneic hematopoietic cell transplantation. A study from the Acute Leukemia Working Party of the European Society for Blood and Marrow TransplantationSebastian Giebel, Myriam Labopin, Thomas Schroeder, et al.
Pageof 45

Showing results (171-180 of 443) with videos related to

Sort By:
Pageof 45
Leukemia|November 16, 2019
The impact of anti-thymocyte globulin on the outcomes of Patients with AML with or without measurable residual disease at the time of allogeneic hematopoietic cell transplantationArnon Nagler, Bhagirathbhai Dholaria, Myriam Labopin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 21, 2018
Impact of Donor Type in Patients with AML Given Allogeneic Hematopoietic Cell Transplantation After Low-Dose TBI-Based RegimenFrédéric Baron, Myriam Labopin, Annalisa Ruggeri, et al.
Haematologica|September 11, 2016
Upfront autologous stem cell transplantation for newly diagnosed elderly multiple myeloma patients: a prospective multicenter studyLaurent Garderet, Eric Beohou, Denis Caillot, et al.
Vaccine|February 2, 2010
Immune response to the 23-valent polysaccharide pneumococcal vaccine after the 7-valent conjugate vaccine in allogeneic stem cell transplant recipients: results from the EBMT IDWP01 trialCatherine Cordonnier, Myriam Labopin, Virginie Chesnel, et al.
Haematologica|March 15, 2015
The impact of graft-versus-host disease prophylaxis in reduced-intensity conditioning allogeneic stem cell transplant in acute myeloid leukemia: a study from the Acute Leukemia Working Party of the European Group for Blood and Marrow TransplantationMarie Thérèse Rubio, Myriam Labopin, Didier Blaise, et al.
Bone Marrow Transplantation|June 21, 2020
The outcome of two or more HLA loci mismatched unrelated donor hematopoietic cell transplantation for acute leukemia: an ALWP of the EBMT studyArnon Nagler, Bhagirathbhai Dholaria, Myriam Labopin, et al.
Bone Marrow Transplantation|May 30, 2023
Long-term outcome of second allogeneic hematopoietic stem cell transplantation (HSCT2) for primary graft failure in patients with acute leukemia in remission: A study on behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow TransplantationArnon Nagler, Myriam Labopin, Ryszard Swoboda, et al.
Cancer|June 22, 2019
Individualized prediction of leukemia-free survival after autologous stem cell transplantation in acute myeloid leukemiaRoni Shouval, Myriam Labopin, Norbert C Gorin, et al.
Journal of Hematology & Oncology|July 6, 2019
Leukemia relapse following unmanipulated haploidentical transplantation: a risk factor analysis on behalf of the ALWP of the EBMTSimona Piemontese, Ariane Boumendil, Myriam Labopin, et al.
American Journal of Hematology|January 10, 2023
Fludarabine versus cyclophospamide in combination with myeloablative total body irradiation as conditioning for patients with acute myeloid leukemia treated with allogeneic hematopoietic cell transplantation. A study from the Acute Leukemia Working Party of the European Society for Blood and Marrow TransplantationSebastian Giebel, Myriam Labopin, Thomas Schroeder, et al.
Pageof 45